Tarsus Pharmaceuticals (TARS) Other Non-Current Assets (2019 - 2026)

Tarsus Pharmaceuticals' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets fell 21.93% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (down 21.93% YoY), while the FY2025 annual figure was $2.0 million, down 23.0% from the prior year.
• Other Non-Current Assets was $2.0 million for Q1 2026 at Tarsus Pharmaceuticals, roughly flat from $2.0 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $2.6 million in Q4 2024 to a low of $529000.0 in Q1 2023.
• Historically, Other Non-Current Assets has averaged $1.5 million across 5 years, with a median of $1.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets slumped 63.9% in 2022, then jumped 202.96% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $585000.0 in 2022, then surged by 114.19% to $1.3 million in 2023, then surged by 107.5% to $2.6 million in 2024, then declined by 23.0% to $2.0 million in 2025, then dropped by 0.05% to $2.0 million in 2026.
• The last three Other Non-Current Assets figures came in at $2.0 million (Q1 2026), $2.0 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.